Is TB-500 actually better than GHK-Cu

TB-500 and GHK-Cu show up together constantly, most visibly as two of the three peptides in the GLOW stack, and I get some version of "which one actually works better" almost every week from people building their first protocol. Short answer: neither TB-500 nor GHK-Cu is better in an absolute sense, because they are solving different problems. TB-500 is a systemic repair coordinator built around cell migration and vascular repair. GHK-Cu is a collagen and connective-tissue remodeler built around copper delivery. If you're comparing them for the same injury, you're usually asking the wrong question.

I've had this conversation with clients who bought TB-500 for a stubborn tendon issue and were disappointed that their skin didn't look different, and with people who bought GHK-Cu expecting it to fix a torn muscle the way TB-500 would. Neither peptide failed. They were doing exactly what they're built to do, just not what the buyer expected.

The mechanism split, and why it matters more than the marketing

TB-500 is a fragment of thymosin beta-4, a protein your body already uses to manage the actin scaffolding inside cells. That actin control is what lets cells crawl toward an injury site, and migration is the first step in nearly every repair process. On top of that, TB-500 promotes new blood vessel formation and dials down inflammatory and fibrotic signaling, which is part of why it's studied for angiogenesis and anti-inflammatory, anti-fibrotic effects across a wide range of tissue types, including cardiac, dermal, kidney, and liver models. The core mechanism, actin sequestration, is the best-characterized part of the whole picture, documented in vitro.

GHK-Cu works differently. It's a copper-carrying tripeptide that shuttles copper to the enzymes that cross-link collagen and elastin into functional tissue, and it also acts as a signaling molecule that tells fibroblasts to lay down more collagen, elastin, and the water-holding gel that keeps skin plump. Its animal wound-chamber data shows a dose-dependent increase in connective tissue, and its topical data has the deepest human track record of nearly anything in this category, including a diabetic foot ulcer trial that showed substantially faster wound closure than vehicle.

So when someone asks whether TB-500 is "better," you have to ask better for what. For a torn muscle, a joint issue, or anything where the limiting factor is getting repair cells to the site and keeping blood flow adequate, TB-500's mechanism is the closer fit. For skin quality, scar texture, or anything where the limiting factor is collagen architecture, GHK-Cu's mechanism is the closer fit.

Evidence quality: neither one has what you'd want, but for different reasons

Here's the part that gets glossed over in most comparisons I read. Neither compound has a published human trial of the actual injectable product people buy.

TB-500's animal record is deep and mechanistically coherent, spanning cardiac repair and dermal and diabetic wound healing, plus newer work in liver inflammation and kidney injury. But the human trials that exist for thymosin beta-4 used the clinical-grade, full-length pharmaceutical version, not the gray-market fragment most vendors sell, and even that pharmaceutical version came up short on its primary endpoint in a 2025 heart-attack trial, though an early-dosing subgroup did show a benefit.

GHK-Cu has more human data in absolute terms, but almost all of it is topical. A 2006 cosmetic trial found no significant improvement in wrinkles or redness. A separate 1994 multicenter trial on diabetic foot ulcers found the opposite: substantially faster closure and lower infection rates with GHK-Cu gel than with vehicle. Those two results aren't in conflict once you notice they tested different things: a cosmetic endpoint on already-healthy skin versus a functional endpoint on tissue that's actively failing to heal. For the injectable route specifically, there is no registered human trial at all. What exists is animal data, in vitro mechanism work, and a lot of practitioner-reported experience.

I try to stay evidence-based with peptides, and the honest picture here is that both compounds are running well ahead of formal human trials on the exact use case people are buying them for. That's not unusual in this space, and it doesn't make either one worthless, but it's worth knowing which floor you're standing on before you decide.

Cost, side-effect load, and who each one actually suits

Cost-wise, a 50 mg GHK-Cu vial generally runs cheaper than a comparable milligram dose of TB-500, and a topical GHK-Cu cream is the lowest-cost way into either compound if you just want to test the water. TB-500 tends to be dosed less frequently because of its longer half-life, so weekly injection counts can end up lower even though the per-vial price is higher. Real cost comes down to your protocol, not the sticker price on the box.

Side-effect load is light for both, and neither has a documented serious toxicity signal in the available data. TB-500's most common complaint is injection-site irritation, with occasional mild headache or transient lethargy in the first week that tends to resolve on its own. GHK-Cu's most common complaint is a noticeable sting on injection, driven by its acidic formulation pH and the local copper influx, which most people manage by diluting the reconstituted solution further. GHK-Cu also carries a longer-term consideration TB-500 doesn't: high or sustained copper intake competes with zinc absorption, so people running it for months tend to add zinc alongside it. Both compounds carry a mechanism-based caution around active cancer, since angiogenesis and cell-migration signaling can theoretically support tumor growth as easily as tissue repair, which is worth a conversation with your doctor if that applies to you.

Who each one suits: if you're dealing with a soft-tissue injury, a joint that isn't recovering, or anything where you want systemic repair signaling working in the background, TB-500 is the better-targeted tool, often paired with BPC-157 in the Wolverine stack. If your goal is skin quality, scar remodeling, or connective-tissue density, GHK-Cu is the better-targeted tool, and it has the deeper topical human track record to back that specific use. If you want both angles running at once, that's the actual logic behind GHK-Cu sitting alongside TB-500 in the GLOW stack: TB-500 handles the early migration and vascular work, and GHK-Cu comes in afterward to remodel what's already been mobilized.

On dosing, the studies behind TB-500 mostly used animal models with milligram-per-kilogram amounts that don't translate directly to a human protocol. What the practitioner and user community has actually converged on is a loading phase of 2 to 5 mg injected twice weekly for the first four to six weeks, then a maintenance dose of 2 to 5 mg once weekly or every other week, since TB-500 has a longer effective duration than something like BPC-157 and doesn't need daily dosing. For GHK-Cu, the converged real-world range is 0.5 to 2 mg per day subcutaneously to start, up to around 3 mg per day for more advanced users, typically cycled 8 to 12 weeks on with a break afterward rather than run continuously.

Now the part my lawyer makes me say, and he's right: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

I've been through the process of picking between two peptides that seem to overlap more than they actually do, and the fix is always the same: name the actual problem you're trying to solve before you name the compound. TB-500 and GHK-Cu aren't rivals competing for the same job. They're two different tools that happen to get bundled together because they work well side by side, and knowing which mechanism matches your goal will get you further than any head-to-head ranking ever will.